Replies to post #211353 on Biotech Values

[DewDiligence]

(CHRS/MNTA/AMGN/etc)—Re: ABBV’s ‘135 Humira patent invalidated

This is bullish for all companies seeking to commercialize Humira FoBs for the US market (as noted in #msg-131355570).

Had ABBV’s ‘135 patent been upheld (or should ABBV prevail on appeal to the CAFC, which is very unlikely, IMO), then Humira-FoB labels would have excluded biweekly subcutaneous dosing to treat RA, which is Humira’s largest single indication.